Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Phase 3
Completed
- Conditions
- Asthma
- Registration Number
- NCT00546520
- Lead Sponsor
- AstraZeneca
- Brief Summary
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method PC20FEV1 (AMP)
- Secondary Outcome Measures
Name Time Method Baseline FEV1 from spirometry, exhaled NO, eosinophils, basophils, and mast cells determined from induced sputum; Safety variables: Physical examination, vital signs, ECG, laboratory work-up, and adverse events
Trial Locations
- Locations (1)
"Altana Pharma/Nycomed"
🇬🇧London, United Kingdom